Table of Content

1. Key Insights

2. Executive Summary of Pemphigus Vulgaris (PV)

3. Pemphigus Vulgaris (PV) Epidemiology Overview at a Glance
3.1. Epidemiology Share (%) Distribution of PV in 2017
3.2. Epidemiology Share (%) Distribution of PV in 2030

4. Disease Background and Overview: Pemphigus Vulgaris (PV)
4.1. Introduction
4.2. Clinical Manifestations
4.3. Disease Causes
4.4. Symptom of PV
4.5. Pathophysiology
4.6. PV Diagnosis
4.6.1. Diagnosis of Pemphigus Vulgaris: Recommendations by an International Panel of Experts
4.6.2. Pemphigus S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)

5. Case Reports
5.1. Nail disease in Pemphigus Vulgaris
5.2. Management of oral pemphigus vulgaris: A case report and a clinical update
5.3. Pemphigus Vulgaris and systemic lupus erythematosus in a 46 years old man
5.4. A case of concomitant pemphigus foliaceus and oral pemphigus vulgaris
5.5. A shift in clinical features, histologic findings and antigen profiles from Pemphigus Vulgaris to pemphigus foliaceus – two case studies

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. KOL Views
6.3. Epidemiology Methodology
6.4. Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the 7MM

7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the United States
7.3. Gender-specific Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the United States
7.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the United States
7.5. Severity-specific Diagnosed Prevalent Population of Pemphigus Vulgaris in the United States

8. EU5 Epidemiology
8.1. Germany Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Germany
8.1.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Germany
8.1.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Germany
8.1.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Germany
8.2. France Epidemiology
8.2.1. Assumptions and Rationale
8.2.2. Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in France
8.2.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in France
8.2.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in France
8.2.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in France
8.3. Italy Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Italy
8.3.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Italy
8.3.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Italy
8.3.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Italy
8.4. Spain Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Spain
8.4.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Spain
8.4.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Spain
8.4.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Spain
8.5. United Kingdom Epidemiology
8.5.1. Assumptions and Rationale
8.5.2. Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the UK
8.5.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the UK
8.5.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the United Kingdom
8.5.5. Severity-Specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the United Kingdom

9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Japan
9.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Japan
9.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Japan
9.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Japan

10. Appendix

11. Bibliography
11.1. Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight



List of Figures


Figure 1 Typical features of a patient with PV
Figure 2 Clinical manifestations of Pemphigus
Figure 3 World map showing association of type II HLA genes with PV in different populations, grouped according to geographical regions
Figure 4 Pathogenesis of Pemphigus
Figure 5 Mechanisms of Acantholysis
Figure 6 B-cell and T-cell responses in Pemphigus
Figure 7 A multi-step approach for diagnosing PV
Figure 8 Pemphigus area and activity score
Figure 9 Pemphigus activity score
Figure 10 Pemphigus Disease Area Index
Figure 11 Pemphigus Vulgaris Lesion Severity Score
Figure 12 Harman’s Pemphigus Grading
Figure 13 Kumar’s Scoring system
Figure 14 Mahajan’s Scoring system
Figure 15 Diagnostic recommendations for PV by the International Panel of Experts
Figure 16 US KOL Views
Figure 17 Europe KOL Views
Figure 18 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the 7MM (2017–2030)
Figure 19 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the US (2017–2030)
Figure 20 Gender-Specific Diagnosed Prevalence of PV in the US (2017–2030)
Figure 21 Age-specific Diagnosed Prevalence of PV in the US (2017–2030)
Figure 22 Severity -specific Diagnosed Prevalence of PV in the US (2017–2030)
Figure 23 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Germany (2017–2030)
Figure 24 Gender-Specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Germany (2017–2030)
Figure 25 Age-specific Diagnosed Prevalence of PV in Germany (2017–2030)
Figure 26 Severity-specific Diagnosed Prevalence of PV in Germany (2017–2030)
Figure 27 Diagnosed Prevalent Population of PV in France (2017–2030)
Figure 28 Gender-specific Diagnosed Prevalence of PV in France (2017–2030)
Figure 29 Age-specific Diagnosed Prevalence of PV in France (2017–2030)
Figure 30 Severity-specific Diagnosed Prevalence of PV in France (2017–2030)
Figure 31 Diagnosed Prevalent Population of PV in Italy (2017–2030)
Figure 32 Gender-specific Diagnosed Prevalence of PV in Italy (2017–2030)
Figure 33 Age-specific Diagnosed Prevalence of PV in Italy (2017–2030)
Figure 34 Severity-specific Diagnosed Prevalence of PV in Italy (2017–2030)
Figure 35 Diagnosed Prevalent Population of PV in Spain (2017–2030)
Figure 36 Gender-specific Diagnosed Prevalence of PV in Spain (2017–2030)
Figure 37 Age-specific Diagnosed Prevalence of PV in Spain (2017–2030)
Figure 38 Severity-specific Diagnosed Prevalence of PV in Spain (2017–2030)
Figure 39 Diagnosed Prevalence of PV in the UK (2017–2030)
Figure 40 Gender-Specific Diagnosed Prevalence of PV in the UK (2017–2030)
Figure 41 Age-Specific Diagnosed Prevalence of PV in the UK (2017–2030)
Figure 42 Severity-specific Diagnosed Prevalence of PV in the United Kingdom (2017–2030)
Figure 43 Diagnosed Prevalent Population of PV in Japan (2017–2030)
Figure 44 Gender-specific Diagnosed Prevalence of PV in Japan (2017–2030)
Figure 45 Age-specific Diagnosed Prevalence of PV in Japan (2017–2030)
Figure 46 Severity-specific Diagnosed Prevalence of PV in Japan (2017–2030)


List of Tables


Table 1 Summary of Pemphigus Vulgaris (PV), Epidemiology and Key Events (2017–2030)
Table 2 Drugs associated with PV
Table 3 Association of non-HLA genes with PV
Table 4 Differential diagnosis of oral lesions in PV
Table 5 PV diagnostic algorithm
Table 6 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the 7MM (2017–2030)
Table 7 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the US (2017–2030)
Table 8 Gender-specific Diagnosed Prevalence of PV in the US (2017–2030)
Table 9 Age-specific Diagnosed Prevalence of PV in the US (2017–2030)
Table 10 Severity-specific Diagnosed Prevalence of PV in the US (2017–2030)
Table 11 Total Diagnosed Prevalent Population of PV in Germany (2017–2030)
Table 12 Gender-Specific Diagnosed Prevalence of PV in Germany (2017–2030)
Table 13 Age-specific Diagnosed Prevalence of PV in Germany (2017–2030)
Table 14 Severity-specific Diagnosed Prevalence of PV in Germany (2017–2030)
Table 15 Diagnosed Prevalent Population of PV in France (2017–2030)
Table 16 Gender-specific Diagnosed Prevalence of PV in France (2017–2030)
Table 17 Age-specific Diagnosed Prevalence of PV in France (2017–2030)
Table 18 Severity-specific Diagnosed Prevalence of PV in France (2017–2030)
Table 19 Diagnosed Prevalent Population of PV in Italy (2017–2030)
Table 20 Gender-specific Diagnosed Prevalence of PV1 in Italy (2017–2030)
Table 21 Age-specific Diagnosed Prevalence of PV in Italy (2017–2030)
Table 22 Severity-specific Diagnosed Prevalence of PV in Italy (2017–2030)
Table 23 Diagnosed Prevalent Population of PV in Spain (2017–2030)
Table 24 Gender-specific Diagnosed Prevalence of PV in Spain (2017–2030)
Table 25 Age-specific Diagnosed Prevalence of PV in Spain (2017–2030)
Table 26 Severity-specific Diagnosed Prevalence of PV in Spain (2017–2030)
Table 27 Diagnosed Prevalence of PV in the UK (2017–2030)
Table 28 Gender-Specific Diagnosed Prevalence of PV in the UK (2017–2030)
Table 29 Age-specific Diagnosed Prevalence of PV in the UK (2017–2030)
Table 30 Severity-Specific Diagnosed Prevalence of PV in the United Kingdom (2017–2030)
Table 31 Diagnosed Prevalent Population of PV in Japan (2017–2030)
Table 32 Gender-specific Diagnosed Prevalence of PV in Japan (2017–2030)
Table 33 Age-specific Diagnosed Prevalence of PV in Japan (2017–2030)
Table 34 Severity-specific Diagnosed Prevalence of PV in Japan (2017–2030)